# ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases

> **NCT05265013** · PHASE2 · TERMINATED · sponsor: **Rakuten Medical, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **COMBINATION_PRODUCT:** ASP-1929 Photoimmunotherapy
- **BIOLOGICAL:** pembrolizumab

## Key facts

- **NCT ID:** NCT05265013
- **Lead sponsor:** Rakuten Medical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-19
- **Primary completion:** 2023-11-20
- **Final completion:** 2024-03-29
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2024-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05265013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05265013, "ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05265013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*